

**Session Title:** #178: Gastrointestinal (Noncolorectal) Cancer

**Session Type:** Poster Discussion Session

**Date:** Friday, June 4

**Location:** E450b

**Time:** 2:00 PM - 6:00 PM

- Gastrointestinal (Noncolorectal) Cancer

*Gauri R. Varadhachary, MD*

- Gastrointestinal (Noncolorectal) Cancer

*Andrea Wang-Gillam, MD, PhD*

1 #4013-5-fluorouracil, leucovorin, and oxaliplatin with or without docetaxel in elderly (65 years or older) patients with esophagogastric cancer: FLOT65+ trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO).

*Salah-Eddin Al-Batran*

2 #4014-Random assignment multicenter phase II study of modified docetaxel, cisplatin, fluorouracil (mDCF) versus DCF with growth factor support (GCSF) in metastatic gastroesophageal adenocarcinoma (GE).

*Manish Shah*

3 #4015-Randomized phase II trial of S-1 plus irinotecan versus S-1 plus paclitaxel as first-line treatment for advanced gastric cancer (OGSG0402): Final report.

*Tomono Kishimoto, MD*

5 #4017-Validation of tumoral matrix-metalloproteinase-9 (MMP-9) mRNA expression as a molecular prognostic factor for metastatic gastroesophageal cancer.

*Akin Atmaca*

- Discussion

*Peter C. Enzinger, MD*

6 #4018-Intergroup Trial of Adjuvant Chemotherapy in Adenocarcinoma of the Stomach (ITACA-S) trial: Comparison of a sequential treatment with irinotecan (CPT-11) plus 5-fluorouracil (5FU)/folinic acid (LV) followed by docetaxel and cisplatin versus a 5-FU/LV regimen as postoperative treatment for radically resected gastric cancer: Tolerability and feasibility of a phase III study.

*Emilio Bajetta, MD*

7 #4019-Preliminary safety data from a randomized trial of perioperative epirubicin, cisplatin plus capecitabine (ECX) with or without bevacizumab (B) in patients (pts) with gastric or oesophagogastric junction (OGJ) adenocarcinoma.

*Alicia Frances Clare Okines*

8 #4020-Randomized controlled trial to evaluate splenectomy in total gastrectomy for proximal gastric carcinoma (JCOG0110): Analyzes of operative morbidity, operation time, and blood loss.

*Takeshi Sano*

9 #4021-Perioperative chemotherapy with oxaliplatin/5-fluorouracil/leucovorin (FOLFOX7) for locally advanced gastric cancer: Final results of a prospective multicenter phase II study (BJS-A-01) with 2 years follow-up.

*Jiafu Ji*

10 #4022-Meta-analysis of preoperative chemotherapy (CTX) versus primary surgery for locoregionally advanced adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus (GE adenocarcinoma).

*Ulrich Ronellenfitsch, MD*

11 #4023-Comparison of the 2010 AJCC TNM staging system with a modified lymph node ratio staging system in 7,233 gastric cancer patients.

*Jiping Wang*

- Discussion

*Stephen Swisher, MD*

12 #4024-Effect of peretinoin on recurrence of hepatocellular carcinoma (HCC): Results of a phase II/III randomized placebo-controlled trial.

*Kiwamu Okita*

13 #4025-A randomized phase II/III trial of three weekly cisplatin based transarterial chemoembolization (TACE) versus embolization (TAE) alone for hepatocellular cancer (HCC).

*Tim Meyer*

14 #4026-Study in Asia of the combination of transcatheter arterial chemoembolization (TACE) with sorafenib in patients with hepatocellular carcinoma (HCC) trial (START): Second interim safety and efficacy analysis.

*Young Hwa Chung*

15 #4027-European multicenter evaluation of survival for patients with hepatocellular carcinoma (HCC) treated by radioembolization with 90y-labeled resin microspheres.

*Bruno Sangro*

16 #4028-The impact of antiviral therapy on the outcome of hepatitis B viral (HBV)-related hepatocellular carcinoma (HCC) detected in surveillance program.

*Vincent W.S. Wong*

17 #4029-Randomized phase II trial of s-1 and cisplatin versus gemcitabine and cisplatin in advanced biliary tract adenocarcinoma.

*Myoung Joo Kang*

18 #4030-A randomized phase II study of TSU-68 in patients (pts) with hepatocellular carcinoma (HCC) treated by transarterial chemoembolization (TACE).

*Yasuaki Arai*

- Discussion

*Jennifer J. Knox, MD, FRCP*

19 #4031-Cox proportional hazard analysis of sunitinib (SU) efficacy across subgroups of patients (pts) with progressive pancreatic neuroendocrine tumors (NET).

*Eric Raymond*

20 #4032-The role of octreotide imaging in detecting neuroendocrine tumors (NETs) in 2010: Do we still need it?

*Leonard Saltz*

21 #4033-A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy: Final results of the CONKO-004 trial.

*Hanno Riess*

22 #4034-ECOG 2204: An intergroup randomized phase II study of cetuximab (Ce) or bevacizumab (B) in combination with gemcitabine (G) and in combination with capecitabine (Ca) and radiation (XRT) as adjuvant therapy (Adj Tx) for patients (pts) with completely-resected pancreatic adenocarcinoma (PC).

*Jordan Berlin*

23 #4035-A placebo-controlled, randomized phase II study of conatumumab (C) or AMG 479 (A) or placebo (P) plus gemcitabine (G) in patients (pts) with metastatic pancreatic cancer (mPC).

*Hedy Lee Kindler*

24 #4036-The combination of a chemotherapy doublet (gemcitabine plus capecitabine) with a biologic doublet (bevacizumab plus erlotinib) in patients with advanced pancreatic adenocarcinoma: The TARGET study.

*David J. Watkins*

25 #4037-A multicenter randomized controlled trial of gemcitabine (G) alone versus gemcitabine and s-1 combination therapy (GS) in patients with unresectable advanced pancreatic cancer (PC): GEMSAP study.

*Yousuke Nakai*

- Discussion

*Milind M. Javle, MD*

---

**Session Title:** #245: Gastrointestinal (Noncolorectal) Cancer

**Session Type:** Poster Discussion Session

**Date:** Friday, June 4

**Location:** E354a

**Time:** 5:00 PM - 6:00 PM

- Gastrointestinal (Noncolorectal) Cancer

*Andrea Wang-Gillam, MD, PhD*

- Gastrointestinal (Noncolorectal) Cancer

*Gauri R. Varadhachary, MD*

1 #4013-5-fluorouracil, leucovorin, and oxaliplatin with or without docetaxel in elderly (65 years or older) patients with esophagogastric cancer: FLOT65+ trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO).

*Salah-Eddin Al-Batran*

2 #4014-Random assignment multicenter phase II study of modified docetaxel, cisplatin, fluorouracil (mDCF) versus DCF with growth factor support (GCSF) in metastatic gastroesophageal adenocarcinoma (GE).

*Manish Shah*

3 #4015-Randomized phase II trial of S-1 plus irinotecan versus S-1 plus paclitaxel as first-line treatment for advanced gastric cancer (OGSG0402): Final report.

*Tomono Kishimoto, MD*

5 #4017-Validation of tumoral matrix-metalloproteinase-9 (MMP-9) mRNA expression as a molecular prognostic factor for metastatic gastroesophageal cancer.

*Akin Atmaca*

- Discussion

*Peter C. Enzinger, MD*

6 #4018-Intergroup Trial of Adjuvant Chemotherapy in Adenocarcinoma of the Stomach (ITACA-S) trial: Comparison of a sequential treatment with irinotecan (CPT-11) plus 5-fluorouracil (5FU)/folinic acid (LV) followed by docetaxel and cisplatin versus a 5-FU/LV regimen as postoperative treatment for radically resected gastric cancer: Tolerability and feasibility of a phase III study.

*Emilio Bajetta, MD*

7 #4019-Preliminary safety data from a randomized trial of perioperative epirubicin, cisplatin plus capecitabine (ECX) with or without bevacizumab (B) in patients (pts) with gastric or oesophagogastric junction (OGJ) adenocarcinoma.

*Alicia Frances Clare Okines*

8 #4020-Randomized controlled trial to evaluate splenectomy in total gastrectomy for proximal gastric carcinoma (JCOG0110): Analyzes of operative morbidity, operation time, and blood loss.

*Takeshi Sano*

9 #4021-Perioperative chemotherapy with oxaliplatin/5-fluorouracil/leucovorin (FOLFOX7) for locally advanced gastric cancer: Final results of a prospective multicenter phase II study (BJS-A-01) with 2 years follow-up.

*Jiafu Ji*

10 #4022-Meta-analysis of preoperative chemotherapy (CTX) versus primary surgery for locoregionally advanced adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus (GE adenocarcinoma).

*Ulrich Ronellenfitsch, MD*

11 #4023-Comparison of the 2010 AJCC TNM staging system with a modified lymph node ratio staging system in 7,233 gastric cancer patients.

*Jiping Wang*

- Discussion

*Stephen Swisher, MD*

12 #4024-Effect of peretinoin on recurrence of hepatocellular carcinoma (HCC): Results of a phase II/III randomized placebo-controlled trial.

*Kiwamu Okita*

13 #4025-A randomized phase II/III trial of three weekly cisplatin based transarterial chemoembolization (TACE) versus embolization (TAE) alone for hepatocellular cancer (HCC).

*Tim Meyer*

14 #4026-Study in Asia of the combination of transcatheter arterial chemoembolization (TACE) with sorafenib in patients with hepatocellular carcinoma (HCC) trial (START): Second interim safety and efficacy analysis.

15 #4027-European multicenter evaluation of survival for patients with hepatocellular carcinoma (HCC) treated by radioembolization with 90y-labeled resin microspheres.

*Bruno Sangro*

16 #4028-The impact of antiviral therapy on the outcome of hepatitis B viral (HBV)-related hepatocellular carcinoma (HCC) detected in surveillance program.

*Vincent W.S. Wong*

17 #4029-Randomized phase II trial of s-1 and cisplatin versus gemcitabine and cisplatin in advanced biliary tract adenocarcinoma.

*Myoung Joo Kang*

18 #4030-A randomized phase II study of TSU-68 in patients (pts) with hepatocellular carcinoma (HCC) treated by transarterial chemoembolization (TACE).

*Yasuaki Arai*

- Discussion

*Jennifer J. Knox, MD, FRCP*

19 #4031-Cox proportional hazard analysis of sunitinib (SU) efficacy across subgroups of patients (pts) with progressive pancreatic neuroendocrine tumors (NET).

*Eric Raymond*

20 #4032-The role of octreotide imaging in detecting neuroendocrine tumors (NETs) in 2010: Do we still need it?

*Leonard Saltz*

21 #4033-A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy: Final results of the CONKO-004 trial.

*Hanno Riess*

22 #4034-ECOG 2204: An intergroup randomized phase II study of cetuximab (Ce) or bevacizumab (B) in combination with gemcitabine (G) and in combination with capecitabine (Ca) and radiation (XRT) as adjuvant therapy (Adj Tx) for patients (pts) with completely-resected pancreatic adenocarcinoma (PC).

*Jordan Berlin*

23 #4035-A placebo-controlled, randomized phase II study of conatumumab (C) or AMG 479 (A) or placebo (P) plus gemcitabine (G) in patients (pts) with metastatic pancreatic cancer (mPC).

*Hedy Lee Kindler*

24 #4036-The combination of a chemotherapy doublet (gemcitabine plus capecitabine) with a biologic doublet (bevacizumab plus erlotinib) in patients with advanced pancreatic adenocarcinoma: The TARGET study.

*David J. Watkins*

25 #4037-A multicenter randomized controlled trial of gemcitabine (G) alone versus gemcitabine and s-1 combination therapy (GS) in patients with unresectable advanced pancreatic cancer (PC): GEMSAP study.

*Yousuke Nakai*

- Discussion

*Milind M. Javle, MD*

---

**Session Title:** #268: Opening Session with Presidential Address, NCI Director's Address, David A. Karnofsky Memorial Award Lecture, and The ASCO Cancer Foundation Donor Recognition Awards

**Session Type:** Special Session

**Date:** Saturday, June 5

**Location:** N Hall B1

**Time:** 9:30 AM - 12:00 PM

- Opening Session with Presidential Address, NCI Director's Address, David A. Karnofsky Memorial Award Lecture, and The ASCO Cancer Foundation Donor Recognition Awards

*Daniel D. Von Hoff, MD*

---

**Session Title:** #219: Targeted Therapy for Neuroendocrine Tumors: Efficacy, Imaging, and Quality of Life

**Session Type:** Clinical Science Symposium

**Date:** Saturday, June 5

**Location:** N Hall B1

**Time:** 1:15 PM - 2:45 PM

- Targeted Therapy for Neuroendocrine Tumors: Efficacy, Imaging, and Quality of Life

*Colin D. Weekes, MD, PhD*

- Targeted Therapy for Neuroendocrine Tumors: Efficacy, Imaging, and Quality of Life

*David Linehan, MD*

- #4000-Updated safety and efficacy results of the phase III trial of sunitinib (SU) versus placebo (PBO) for treatment of pancreatic neuroendocrine tumors (NET).

*Patricia Niccoli*

- #4001-A prospective, multi-institutional phase II study of GW786034 (pazopanib) and depot octreotide (sandostatin LAR) in advanced low-grade neuroendocrine carcinoma (LGNEC).

*Alexandria T. Phan, MD*

- #4002-Randomized run-in study of bevacizumab (B) and everolimus (E) in low- to intermediate-grade neuroendocrine tumors (LGNETs) using perfusion CT as functional biomarker.

*James C. Yao, MD*

- Discussion

*Kjell E. Oberg, MD, PhD*

- #4003-Patient-reported outcomes (PROs) in patients (pts) with pancreatic neuroendocrine tumors (NET) receiving sunitinib (SU) in a phase III trial.

*Aaron Vinik, MD, PhD*

- Discussion

*Ian Chau, MD*

---

**Session Title:** #107: Update on Gastrointestinal Noncolorectal Malignancies: What's New since the 2009 ASCO Annual Meeting?

**Session Type:** Education Session

**Date:** Saturday, June 5

**Location:** N Hall B1

**Time:** 3:00 PM - 4:15 PM

- Review of the results of surgical trials including neoadjuvant and adjuvant therapy in upper GI malignancies over the past year

*Mark Krasna, MD*

- Progress in the Treatment of Esophageal and Gastric Cancers: What's New Since ASCO 2009

*Albert C. Lockhart, MD*

- Hepatobiliary and pancreatic cancers since ASCO 2009: steady steps forward and a long way to go

*Anthony B. El-Khoueiry, MD*

**Session Title:** #167: Highlights of the Day I including Clinical Trials Participation Awards

**Session Type:** Highlights of the Day

**Date:** Sunday, June 6

**Location:** E Hall D1

**Time:** 7:30 AM - 9:00 AM

- Highlights of the Day I including Clinical Trials Participation Awards  
*Everett E. Vokes, MD*
- Clinical Trials Participation Awards  
*Douglas W. Blayney, MD*
- Discussion: Lymphoma and Plasma Cell Disorders  
*Bruce D. Cheson, MD*
- Discussion: Lung Cancer - Local/Regional and Adjuvant Therapy  
*Alan B Sandler, MD*
- Discussion: Patient and Survivor Care  
*Gretchen Genevieve Kimmick, MD*
- Discussion: Melanoma/Skin Cancers  
*F. Stephen Hodi, MD*

**Session Title:** #143: Plenary Session including Science of Oncology Award and Lecture

**Session Type:** Plenary Session

**Date:** Sunday, June 6

**Location:** N Hall B1

**Time:** 1:00 PM - 4:00 PM

- Plenary Session including Science of Oncology Award and Lecture  
*Douglas W. Blayney, MD*
- Plenary Session including Science of Oncology Award and Lecture  
*Daniel F. Hayes, MD*
- Plenary Session including Science of Oncology Award and Lecture  
*Frank McCormick, PhD, FRS*
- #LBA1-Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or Fallopian tube cancer (FTC): A Gynecologic Oncology Group study.

- #2-Weekly paclitaxel combined with monthly carboplatin versus single-agent therapy in patients age 70 to 89: IFCT-0501 randomized phase III study in advanced non-small cell lung cancer (NSCLC).

*Elisabeth A. Quoix*

- #3-Clinical activity of the oral ALK inhibitor, PF-02341066, in ALK-positive patients with non-small cell lung cancer (NSCLC).

*Yung-Jue Bang*

- Discussion

*Martin J. Edelman, MD*

- #4-A phase III, randomized, double-blind, multicenter study comparing monotherapy with ipilimumab or gp100 peptide vaccine and the combination in patients with previously treated, unresectable stage III or IV melanoma.

*Steven O'Day, MD*

- Discussion: Ipilimumab: The light at the end of the tunnel?

*Vernon K Sondak, MD*

**Session Title:** #200: Gastrointestinal (Noncolorectal) Cancer

**Session Type:** General Poster Session

**Date:** Sunday, June 6

**Location:** S Hall A2

**Time:** 2:00 PM - 6:00 PM

18A #4038-Linifanib phase II trial in patients with advanced hepatocellular carcinoma (HCC).

*Han Chong Toh*

18B #4039-Phase I/II study of MK-0646, the humanized monoclonal IGF-1R antibody in combination with gemcitabine or gemcitabine plus erlotinib (E) for advanced pancreatic cancer.

*Milind M. Javle, MD*

18C #4040-Clinicopathologic characteristics of microsatellite instability (MSI) tumors in resected gastric cancer patients.

*Hyeon Jin Cho*

18D #4041-Phase II study of NK105, a paclitaxel-incorporating micellar nanoparticle as second-line treatment for advanced or recurrent gastric cancer.

*Keisho Chin*

18E #4042-Meta-analyses of randomized trials assessing the effect of neoadjuvant chemotherapy in locally advanced gastric cancer.

*Haoran Li*

18F #4043-KRAS, BRAF mutations. and HER2 expression in patients operated for pancreatic adenocarcinomas.

*Nicolai Aagaard Schultz*

18G #4044-Prospective analysis of clinical outcomes and prognostic factors in patients with neuroendocrine tumors (NETs).

*Monica Ter-Minassian*

18H #4045-Comparative effectiveness of radioembolization and the standard of care for hepatocellular carcinoma: Is a randomized survival study feasible?

*Riad Salem, MD, MBA*

19A #4046-Molecular predictors of response to antiangiogenic therapy in HCC: Data from bevacizumab and erlotinib phase II study.

*Ahmed Omar Kaseb*

19B #4047-Association of germline polymorphisms in genes involved in the CD44 pathway and clinical outcome in localized gastric adenocarcinoma (GA).

*Yan Ning*

19C #4048-(Q)-TWiST analysis of trastuzumab plus fluoropyrimidine/cisplatin (T-XP/FP) versus XP/FP alone as first-line therapy for advanced HER2-positive gastric cancer.

*Hyun Cheol Chung, MD, D.Phil.*

19D #4049-Setting the standard for advanced pancreatic ductal adenocarcinoma (A-PDAC) in 2010: Meta-regression and power analysis of phase III randomized clinical trials (RCT) evaluating gemcitabine (GEM) in combination with cisplatin (CIS), oxaliplatin (L-OHP), or capecitabine (CAP).

*Isabella Sperduti*

19E #4050-Final results of a phase II study of modified FOLFOX6 (mFOLFOX6) and erlotinib (E) in patients with metastatic adenocarcinoma of the esophagus (Eso) and gastroesophageal junction (GEJ).

*Zev A. Wainberg*

19F #4051-^Efficacy and safety of sorafenib (Sor) in patients (Pts) with advanced hepatocellular carcinoma (HCC): Subgroup analyses of the SHARP trial by baseline (BL) transaminase (ALT/AST)/ $\alpha$ ; -fetoprotein (AFP) and bilirubin (bil) levels.

*Jean-Luc Raoul*

19G #4052-Randomized phase II study of best-available 5-fluorouracil (5-FU) versus weekly paclitaxel in gastric cancer (GC) with peritoneal metastasis (PM) refractory to 5-FU-containing regimens (JCOG0407).

*Hiroya Takiuchi*

19H #4053-A multicenter randomized phase II (rPII)/ III study comparing concurrent chemoradiotherapy (CRT) with low-dose cisplatin plus continuous infusion of 5-fluorouracil (LDPF) and standard-dose PF (SDPF) for locally advanced unresectable squamous cell carcinoma of the thoracic esophagus (JCOG0303).

*Masayuki Shinoda*

20A #4054-Association of germline polymorphism in the SPARC gene and tumor recurrence in patients with resected gastric cancer.

*Peter M.D. Wilson*

20B #4055-Ten-year experience of percutaneous radiofrequency ablation for hepatocellular carcinoma.

*Shuichiro Shiina*

20C #4056-An analysis of the effect of smoking status on erlotinib pharmacokinetics (PKs), toxicity, and ability to dose escalate in a phase II study of erlotinib in advanced pancreatic cancer (PC).

*Daniel John Renouf*

20D #4057-Interim safety analysis from TYTAN: A phase III Asian study of lapatinib in combination with paclitaxel as second-line therapy in gastric cancer.

*Taroh Satoh*

20E #4058-A multicenter phase II trial of S-1 with concurrent radiotherapy for locally advanced pancreatic cancer.

*Tatsuya Ioka*

20F #4059-Effect of hyperacute immunotherapy in addition to standard adjuvant therapy for resected pancreatic cancer on disease-free and overall survival: Preliminary analysis of phase II data.

*Jeffrey M Hardacre, MD*

20G #4060-Randomized phase II trial with an uPA inhibitor (WX-671) in patients with locally advanced nonmetastatic pancreatic cancer.

*Volker Heinemann*

20H #4061-Survival prolongation after treatment failure in patients with advanced gastric cancer (AGC): Results from combined analysis of JCOG9205 and JCOG9912.

*Atsuo Takashima*

21A #4062-A single-institution (MSKCC) analysis of incidence and clinical outcomes in patients with thromboembolic events and exocrine pancreas cancer.

*Andrew S. Epstein*

21B #4063-Prognostic values of baseline circulating endothelial progenitor level for advanced hepatocellular carcinoma (HCC) patients under antiangiogenic therapy.

*Yu Yun Shao*

21C #4064-E2205: A phase II study to measure response rate and toxicity of neoadjuvant chemoradiotherapy (CRT) with oxaliplatin (OX) and infusional 5-fluorouracil (5-FU) plus cetuximab (C) followed by postoperative docetaxel (DT) and C in patients with operable adenocarcinoma of the esophagus.

*Michael K. Gibson*

21D #4065-Prognostic significance of xCT gene single nucleotide polymorphisms (SNPs) in patients (pts) with advanced pancreatic cancer (PC) treated with gemcitabine (GEM) plus platinum analogues (PLAT).

*Tzu-chuan Jane Huang*

21E #4066-Sorafenib plus chemotherapy versus chemotherapy alone in advanced pancreatic cancer: A randomized phase II trial.

*Stefano Cascinu*

21F #4067-Significance of pathologic response to preoperative therapy in pancreatic cancer.

*Yun Shin Chun, MD*

21G #4163-A phase II clinical trial of MK-0646, an insulin-like growth factor-1 receptor inhibitor (IGF-1R), in patients with metastatic well-differentiated neuroendocrine tumors (NETs).

*Diane Lauren Reidy*

21H #4069-Predictive value of restaging after induction concurrent chemoradiotherapy (CCRT) for locoregionally advanced (LRA) adenocarcinoma (ACA) of the esophagus and gastroesophageal junction (GEJ).

*Brooke E Phillips*

22A #4070-Trastuzumab and capecitabine in patients with HER2-expressing metastatic pancreatic cancer: A multicenter phase II study of the German AIO Pancreatic Cancer Group (AIO PK-0204).

*Michael Geissler*

22B #4071-Is minimally invasive esophagectomy for cancer decreasing pulmonary complications? Results from a case-control study.

*Nicolas Briez*

22C #4072-Multicenter phase II study of SIR-sphere plus sorafenib as first-line treatment in patients with nonresectable hepatocellular carcinoma: The Asia-Pacific Hepatocellular Carcinoma Trials Group Protocol 05 (AHCC05).

*Pierce KH Chow, MD, PhD*

22D #4073-Phase II trials (P2T) in advanced pancreatic cancer (APC): Systematic review with focus on the design, entry criteria, and endpoints used.

*Anastasios Stathis*

22E #4074-Extended safety and efficacy data on triple combination therapy using s-1, cisplatin, and paclitaxel in patients with advanced gastric cancer in a multicenter phase II study.

*Hiroaki Iwase*

22F #4075-Perioperative docetaxel, cisplatin, and 5-fluorouracil (DCF) for locally advanced esophageal and gastric adenocarcinoma: Safety and response results from a multicenter phase II trial.

*Lorenzo E Ferri*

22G #4076-A phase II randomized double blind multicenter trial of gemcitabine (Gem) plus imexon (IMX) versus Gem plus placebo (P) in patients with chemotherapy-naïve pancreatic adenocarcinoma (PC).

*Steven J. Cohen*

22H #4077-The impact of socioeconomic status upon specialist consultation, treatment, and outcomes for pancreatic adenocarcinoma.

*James E Carroll*

23A #4078-Registry of Gastric Cancer Treatment Evaluation (REGATE): Regional differences in surgical approaches.

*Mikhail Ter-Ovanesov*

23B #4079-Comorbidity and overall survival (OS) in patients with advanced pancreatic cancer (APC): Results from NCIC CTG PA.3-A phase III trial of erlotinib plus gemcitabine (E+G) versus gemcitabine (G) alone.

*Michael M. Vickers*

23C #4080-Hereditary gastric cancer caused by germline CDH1 gene mutations in the Netherlands.

*Irma Kluijt*

23D #4081-Early toxicity of sunitinib as a potential predictive biomarker in advanced hepatocellular carcinoma (HCC) patients.

*Gabriel Dan Duda*

23E #4082-Registry of Gastric Cancer Treatment Evaluation (REGATE): Geographic analysis of baseline characteristics of 10,124 patients (pts).

*John Raymond Zalcborg*

23F #4083-A phase II study of ramucirumab as first-line monotherapy in patients (pts) with advanced hepatocellular carcinoma (HCC).

*Andrew X. Zhu*

23G #4084-Prognostic significance of cell cycle regulating protein expressions in gastric carcinoma patients receiving adjuvant chemotherapy.

*Young Soo Park*

23H #4085-Neoadjuvant paclitaxel poliglumex (PPX), cisplatin, and radiation (RT) for esophageal cancer.

*Thomas Ng*

24A #4086-Phase II trial of ixabepilone (IXA) plus cetuximab (C) as first-line therapy for advanced pancreatic carcinoma (PC).

*Caio Max S. Rocha Lima*

24B #4087-Outcome of patients with recurrent hepatocellular carcinoma after liver transplantation.

*Armin Finkenstedt*

24C #4088-Relapse of hepatocellular carcinoma (HCC) after liver transplantation (LT): A single-center analysis on 139 patients in the sorafenib era.

*Tulio Eduardo Flesch Pfiffer*

24D #4089-Survival of complete responder patients treated for esophageal cancer with chemoradiotherapy followed by surgery as compared to chemioradiotherapy alone: Case-control study.

*Mathieu Messenger*

24E #4090-Registry of Gastric Cancer Treatment Evaluation (REGATE): Staging and diagnosis of 10,124 patients (pts).

*Chew-Wun Wu*

24F #4091-FOLFOX6 as first-line treatment in metastatic gastric cancer: Preliminary results of a phase II trial.

*Annalisa Fontana*

24G #4092-Outcome prediction in hepatocellular carcinoma (HCC): Comparison of alphafetoprotein (AFP) response and conventional radiologic criteria during sorafenib treatment.

*Nicola Personeni*

24H #4093-Association of human epidermal growth factor receptor 2 (HER2) Ile655Val polymorphism (plrm) and gender-specific time to tumor recurrence (TTR) in patients (pts) with localized gastric adenocarcinoma (GA).

*Edwin Yung-Mu Lin, MD*

25A #4094-A phase II, open label study to evaluate the relationship between skin rash and survival in patients with unresectable and/or metastatic pancreatic cancer treated with erlotinib combined with gemcitabine.

*Jose Luis Manzano*

25B #4095-Association between smoking history and disease-free and overall survival in resected gastric cancer.

*Elizabeth Catherine Smyth*

25F #4096-Optimal assessment of treatment benefit with targeted agents for hepatocellular carcinoma (HCC): An analysis of brivanib phase II data.

*Richard S. Finn*

25G #4097-A phase I dose-finding and pharmacodynamic study of rapamycin in combination with bevacizumab in patients with unresectable hepatocellular carcinoma.

*SuPin Choo*

25H #4098-Association between DNA repair polymorphisms and survival in pancreatic cancer patients treated with combination chemotherapy.

*Paola Pacetti*

26A #4099-Docetaxel, oxaliplatin, and capecitabine (TEX Regimen) in patients with advanced or metastatic gastric or gastroesophageal cancer (GC): Results from a phase II trial of the German AIO group.

*Dirk Arnold*

26B #4100-Gene expression profile (GEP) for the prediction of pathologic complete response (pCR): Preliminary data from a neoadjuvant study of capecitabine (C), oxaliplatin (OXP), and radiation (RT) for esophageal cancer (EC).

*Nikhil I. Khushalani*

26F #4101-Role of IL-6 in cachexia progression in advanced pancreatic cancer.

*Shuichi Mitsunaga*

26G #4102-Treatment of advanced or metastatic hepatocellular cancer (HCC): Interim analysis of a single- arm phase II study of bevacizumab and RAD001.

*Gerhard Treiber*

26H #4103-HER2 status of gastric and gastroesophageal cancer (GC) patients assessed by immunohistochemistry (IHC), fluorescence in situ hybridization (FISH) and high-resolution array comparative genomic hybridization (aCGH).

*Yelena Yuriy Janjigian*

27A #4104-A phase II study of capecitabine, oxaliplatin, and bevacizumab for metastatic or unresectable neuroendocrine tumors.

*Pamela L. Kunz*

27B #4105-Utility of post-treatment FDG-PET in predicting outcomes in anal cancer managed with chemoradiotherapy.

*Alexander Graham Heriot*

27C #4106-Concurrent chemoradiotherapy with cetuximab plus twice weekly paclitaxel and cisplatin followed by esophagectomy for locally advanced esophageal squamous cell carcinoma.

*Chih-Hung Hsu*

27D #4107-Phase II study of cetuximab in combination with modified FOLFIRI in patients with advanced gastric cancer who failed first-line chemotherapy (EFFI study).

*Jin Li*

27E #4108-A phase II trial of preoperative chemoradiation therapy plus bevacizumab and erlotinib in the treatment of localized esophageal cancer.

*Anthony Alan Meluch*

27F #4109-Overall survival and clinically deficient quality of life in patients with esophageal cancer or Barrett's esophagus: A Mayo Clinic esophageal adenocarcinoma and Barrett's Esophagus Registry consortium study.

*Robert Clell Miller*

27G #4110-Somatostatin analogue therapy and PROMIS health-related quality-of-life scores in patients with neuroendocrine tumors.

*Mei Dong*

27H #4111-Impact of a novel inflammation-based prognostic system on patients undergoing surgery for hepatocellular carcinoma: A retrospective study of 398 Japanese patients.

*Mitsuru Ishizuka*

28A #4112-Intensity-modulated radiotherapy for esophageal cancer: Analysis of toxicity and outcomes.

*Naamit Kurshan*

28B #4113-Role of surveillance CT scans in resected PC: Correlation with CA19-9 and symptoms.

*Vanja Vaccaro*

28C #4114-Is diabetes mellitus (DM) associated with worse outcomes in pancreatic cancer (PC)?

*Olugbenga O Olowokure, MD, MBBS*

28D #4115-Therapeutic effects of fractionated radioimmunotherapy (RAIT) with clivatuzumab tetraxetan combined with low-dose gemcitabine (Gem) in advanced pancreatic cancer (APC).

*Allyson J. Ocean*

28E #4116-Docetaxel, cisplatin, and capecitabine (DCX) as perioperative chemotherapy in gastroesophageal adenocarcinoma: A phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)

*Peter C. Thuss-Patience*

28F #4117-Association of diabetes with perineural invasion and overall survival in surgically resected patients with pancreatic cancer.

*Mohamed Ahmed Shama*

28G #4118-Registry of Gastric Cancer Treatment Evaluation (REGATE): Variations in nonsurgical therapies.

*Suayib Yalcin*

28H #4119-Diagnostic value of Lens culinaris agglutinin isoform 3 fraction (AFP-L3%) and des-gamma-carboxy prothrombin (DCP) for the diagnosis of hepatocellular carcinoma in cirrhotic patients.

*Raffaella Romeo*

29A #4120-A phase II trial of nab-paclitaxel (NP) in patients with advanced pancreatic cancer (PC) who have progressed on gemcitabine(G)-based therapy.

*Peter Joel Hosein*

29B #4121-*Helicobacter pylori* infection as an independent prognostic factor for locally advanced gastric cancer with curative resection.

*Seok Yun Kang*

29C #4122-Results of a phase II multicenter study of neoadjuvant s-1 and irinotecan in patients with locally advanced gastric cancer.

*Masanori Terashima*

30A #4123-Prognostic markers for response and overall survival in patients with esophageal adenocarcinoma treated with neoadjuvant therapy.

*Jessica M. Leers*

30B #4124-Early outcome of phase II study of preoperative chemotherapy (CX) with s-1 plus cisplatin for stage IV gastric cancer (StIV GC).

*Seiji Satoh, MD, PhD*

30C #4125-Cost-effectiveness of neoadjuvant (NeoAdj) versus adjuvant (Adj) therapies for resectable pancreatic cancer (PC).

*Rachna T. Shroff*

31A #4126-Association of elevated tissue factor (TF) with survival and thromboembolism (TE) in pancreaticobiliary cancers (PBC).

*Anubha Bharthuar*

31B #4127-Characterization and prognostic significance of circulating tumor cells in the peripheral blood of patients with metastatic pancreatic cancer.

*Benjamin P. Negin*

31C #4128-Use of tumor arterial perfusion assessment and RECIST for prediction of survival and residual disease in hepatocellular carcinoma following intra-arterial infusion chemotherapy.

*John R. Daniels*

32A #4129-Analysis of D7S486 in primary gastric cancer and evaluation of TESTIN as a candidate tumor suppressor gene.

*Jianchuan Xia*

32B #4130-Dynamic changes in age, stage distribution, and survival of patients with esophageal adenocarcinoma over three decades in the United States.

*Putao Cen*

32C #4131-Identification of three potential biomarkers in early resectable hepatocellular carcinoma.

*Soo Fan Ang*

33A #4132-Clinical outcomes and survival in patients with hepatocellular carcinoma and HIV infection.

*Massimiliano Berretta*

33B #4133-Analysis of biomarker expression (ki67, EGFR, HER-2, ERK, NFkB, and mTOR) in patients with advanced gastric and gastroesophageal junction (GEJ) cancer treated with cetuximab plus cisplatin/docetaxel: DOCETUX study.

*Carmine Pinto*

33C #4134-A phase I dose escalation trial of CP-675206 (tremelimumab) in combination with gemcitabine in patients with chemotherapy-naive metastatic pancreatic cancer.

*Massimo Aglietta*

34A #4135-Clinical outcome of local recurrence cases after endoscopic mucosal resection (EMR) for Japanese Classification stage 0 esophageal cancer.

*Takako Yoshii*

34B #4136-A phase I study, with expanded cohort, of biweekly fixed-dose rate gemcitabine (FDR GEM) plus capecitabine (CAP) in patients with advanced pancreatic (APC) and biliary carcinomas (ABC).

*Anne Marie Espinoza*

34C #4137-Final results from ARQ 197-114: A phase 1b safety trial evaluating ARQ 197 in cirrhotic patients (pts) with hepatocellular carcinoma (HCC).

*Paolo Zucali*

35A #4138-The utility of PET/CT in the treatment management of gastroesophageal cancer (GEC): Impact on staging and treatment decisions.

*Wen Wen Shan*

35B #4139-Phase I study of sorafenib (S) with gemcitabine (G)-based radiotherapy (G-RT) in patients (pts) with locally advanced unresectable pancreatic adenocarcinoma (LAUPC).

*Stephen Anderson*

35C #4140-Use of serum VEGF (SVEGF) levels to predict outcome of esophageal cancer (EC) patients undergoing preoperative chemoradiation (CRT).

*Fernando De Vita*

35D #4141-Chemoembolization with epirubicin drug-eluting beads (DEB-TACE) to treat early and intermediate hepatocellular carcinoma.

*Antonio Nicolini*

35E #4142-Dose-dense chemotherapy (CT) with modified dose-dense TCF regimen (TCF-dd) in metastatic gastric cancer (MGC): Update of a phase II study.

*Matteo Dalla Chiesa*

35F #4143-Phase II study of oxaliplatin, high-dose capecitabine, and sorafenib in patients with advanced pancreatic cancer.

*Sam Joseph Lubner*

35G #4144-Dose-painted intensity-modulated radiation therapy for anal cancer: A multi-institutional report of acute toxicity and response to therapy.

*Theodore S. Hong, MD*

35H #4145-A multicenter phase II of S-1 in gemcitabine-refractory biliary tract cancer.

*Eiichiro Suzuki*

36A #4146-Upregulation of multidrug resistance-associated protein 4 in the early stage of vascular invasion of hepatocellular carcinoma.

*Keishi Higuchi*

36B #4147-A feasibility analysis from the patient preference randomized phase III clinical trial of second-line chemotherapy (SLC) in advanced gastric cancer (AGC) patients pretreated with both fluoropyrimidines and platinum.

*Se Hoon Park*

36C #4148-Prediction of prognosis in hepatocellular carcinoma based on a gene signature from highly tumorigenic liver cancer cells.

*Xin-Rong Yang*

36D #4149-Phase I and II studies of intravenous Regin-G as monotherapy for stage IVb gemcitabine-resistant pancreatic cancer.

*Howard Bruckner*

36E #4150-Phase II study of FOLFIRI chemotherapy as first-line treatment for elderly patients (pts) with advanced gastric cancer (AGC).

*Yves Becouarn*

36F #4151-Prospective gene signature study using microRNA to predict the tissue of origin (ToO) in pts with cancer of unknown primary site (CUP).

*Gauri R. Varadhachary, MD*

36G #4152-Clinical outcomes in pancreatic adenocarcinoma (PAC) in breast cancer (BC) survivors.

*Maeve Aine Lowery*

36H #4153-Phase II trial of gemcitabine (G), oxaliplatin (O), and erlotinib (T) for the treatment of hepatocellular carcinoma (HCC) and biliary tree cancers (BTC).

*Yehuda Z. Patt*

37A #4154-Maruyama index (MI) and outcomes of gastric cancer resection.

*Jasjit C. Sachdev*

37B #4155-A dose-escalation study of gemcitabine (Gem) plus oxaliplatin (Ox) in combination with imatinib in patients (pts) with gemcitabine-refractory advanced pancreatic adenocarcinoma (PC).

*Naureen Starling*

37C #4156-Prognostic significance of free peritoneal tumor cells in the peritoneal cavity before and after neoadjuvant chemotherapy in patients with gastric cancer undergoing a potentially curative resection.

*Sylvie Lorenzen*

37D #4157-Phase II study of 5-fluorouracil/leucovorin in combination with paclitaxel and oxaliplatin (POF) in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma.

*Rongb-Bo Lin*

37E #4158-Role of MT1-MMP and Kras in invasive pancreatic tumors with pronounced fibrosis.

*Seth B. Krantz*

37F #4159-Lenalidomide for advanced hepatocellular cancer (HCC) in patients progressing on or intolerant to sorafenib.

*Howard Safran*

37G #4160-Analysis of four human PIGF isoforms and of VEGFR-1 in esophageal carcinoma.

*Alexander Schultze*

37H #4161-A phase I/II study of photodynamic therapy (PDT) using HPPH for the treatment of Barrett's and precancerous lesions of the esophagus.

*Hector R Nava*

38A #4162-Tumoral and angiogenesis factors in hepatocellular carcinoma (HCC) after drug eluting bead (DEB) transarterial chemoembolization (TACE) with doxorubicin.

*Alton B Farris*

---

**Session Title:** #99: The Evolution of a Disease: How Does the Changing Epidemiology of Esophagogastric Cancers Affect Treatment Decisions?

**Session Type:** Education Session

**Date:** Sunday, June 6

**Location:** E Hall D1

**Time:** 4:45 PM - 6:00 PM

- Understanding the evolution in epidemiology of esophago-gastric cancer.

*Johanna C. Bendell, MD*

- The molecular continuum of Barrett's esophagus to esophagogastric cancer.

*Jason L Hornick, MD, PhD*

- Using the newest molecular markers in prognosis and risk stratification.

*Janusz Jankowski, PsyD*

---

**Session Title:** #168: Highlights of the Day II including Partners in Progress Award

**Session Type:** Highlights of the Day

**Date:** Monday, June 7

**Location:** E Hall D1

**Time:** 7:30 AM - 9:00 AM

- Highlights of the Day II including Partners in Progress Award

*Kim Allyson Margolin, MD*

- Highlights of the Day II including Partners in Progress Award

*Douglas W. Blayney, MD*

- Partners in Progress Award Recipient

*Ellen V. Sigal, PhD*

- Discussion: Genitourinary (Prostate) Cancer  
*Nicholas J. Vogelzang, MD*
  - Discussion: Gastrointestinal (Colorectal) Cancer  
*Howard S. Hochster, MD*
  - Discussion: Gynecologic Cancer  
*Claire F. Verschraegen, MD*
  - Discussion: Myeloma  
*Jean L. Harousseau, MD*
  - Discussion: Cancer Prevention/Epidemiology  
*Scott Michael Lippman, MD*
- 

**Session Title:** #77: Neoadjuvant versus Adjuvant Chemotherapy and Radiation for Esophagogastric Cancers: Do the Results of Recent Trials Give Us a Direction?

**Session Type:** Education Session

**Date:** Monday, June 7

**Location:** E Hall D2

**Time:** 9:45 AM - 11:00 AM

- (Neo)adjuvant chemotherapy in the management of localized esophagogastric carcinoma.  
*Peter C. Enzinger, MD*
  - Neoadjuvant chemoradiation in the management of localized esophagogastric carcinoma.  
*Mohan Suntharalingam, MD*
  - Implications for surgery following chemotherapy or chemoradiation.  
*Cliff P. Connery, MD*
- 

**Session Title:** #141: Treatment of Barrett's Esophagus to Prevent Esophageal Cancer

**Session Type:** Clinical Problems in Oncology Session

**Date:** Monday, June 7

**Location:** E451a

**Time:** 9:45 AM - 11:00 AM

- Esophageal resection for high-grade dysplasia and superficial cancer  
*Hiran C. Fernando, MD, MBBS*

- Multimodality approaches for endoscopic ablation of Barrett's esophagus

*Kenneth K Wang, MD*

- Risk stratification, chemoprevention and early detection in Barrett's esophagus

*Brian J. Reid, MD, PhD*

---

**Session Title:** #26: Combined Modalities in Pancreatic Cancer: Should Recent Trials Change Our Practice?

**Session Type:** Education Session

**Date:** Monday, June 7

**Location:** N Hall B1

**Time:** 1:15 PM - 2:30 PM

- The role of neoadjuvant vs adjuvant chemotherapy in pancreatic cancer; what does the data tell us?

*Gauri R. Varadhachary, MD*

- Role of radiation in locally advanced pancreatic cancer

*Theodore Steven Lawrence, MD, PhD*

- Surgical approach in resectable and borderline resectable pancreas cancer

*David Linehan, MD*

---

**Session Title:** #151: Gastrointestinal (Noncolorectal) Cancer

**Session Type:** Oral Abstract Session

**Date:** Monday, June 7

**Location:** E Hall D1

**Time:** 3:00 PM - 6:00 PM

- Gastrointestinal (Noncolorectal) Cancer

*Theodore S. Hong, MD*

- Gastrointestinal (Noncolorectal) Cancer

*Alexandria T. Phan, MD*

- #4004-Effect of preoperative concurrent chemoradiotherapy on survival of patients with resectable esophageal or esophagogastric junction cancer: Results from a multicenter randomized phase III study.

*Ate Van Der Gaast*

- #4005-Surgery alone versus chemoradiotherapy followed by surgery for localized esophageal cancer: Analysis of a randomized controlled phase III trial FFCD 9901.

*Christophe Mariette*

- #4006-CALGB 80403/ECOG 1206: A randomized phase II study of three standard chemotherapy regimens (ECF, IC, FOLFOX) plus cetuximab in metastatic esophageal and GE junction cancer.

*Peter C. Enzinger, MD*

- #LBA4007-AVAGAST: a randomized, double-blind, placebo-controlled, phase III study of first-line capecitabine and cisplatin + bevacizumab or placebo in patients with advanced gastric cancer (AGC).

*Yoon-Koo Kang*

- Discussion

*Charles Fuchs, MD*

- #4008-Phase III study of oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX4) versus doxorubicin as palliative systemic chemotherapy in advanced HCC in Asian patients.

*Shukui Qin, MD, MBA*

- #4009-Effect of IFN therapy and amino acid substitutions in the hepatitis C virus (HCV) core region on hepatocarcinogenesis in HCV-related cirrhotic patients.

*Miharu Hirakawa*

- Discussion

*Timothy Pawlik, MD, MPH*

- #4010-Randomized phase III trial comparing FOLFIRINOX (F: 5FU/leucovorin [LV], irinotecan [I] and oxaliplatin [O]) versus gemcitabine (G) as first-line treatment for metastatic pancreatic adenocarcinoma (MPA): Preplanned interim analysis results of the PRODIGE 4/ACCORD 11 trial.

*Thierry Conroy*

- #LBA4011-Gemcitabine plus erlotinib (GE) followed by capecitabine (C) versus capecitabine plus erlotinib (CE) followed by gemcitabine (G) in advanced pancreatic cancer (APC): A randomized, cross-over phase III trial of the Arbeitsgemeinschaft internistische Onkologie (AIO).

*Stefan Boeck, MD*

- #LBA4012-CapRI: Final Results of the Open-label, Multi-center, Randomized Phase III Trial of Adjuvant Chemoradiation Plus Interferon- $\alpha$ 2b (CRI) versus 5-FU Alone for Patients with Resected Pancreatic Adenocarcinoma (PAC)

*Angela Marten*

- Discussion

*Margaret A. Tempero, MD*

---

**Session Title:** #124: Advances in Hereditary Pancreatic Cancer

**Session Type:** Clinical Problems in Oncology Session

**Date:** Monday, June 7

**Location:** E451a

**Time:** 4:45 PM - 6:00 PM

- Pancreatic cancer screening

*Teresa Brentnall, MD*

- Genetics of hereditary pancreatic cancer

*Ralph Hruban, MD*

- Surgical management of hereditary pancreatic cancer

*Sean J. Mulvihill, MD*

---

**Session Title:** #169: Highlights of the Day III

**Session Type:** Highlights of the Day

**Date:** Tuesday, June 8

**Location:** E Hall D1

**Time:** 7:30 AM - 9:00 AM

- Highlights of the Day III

*Kathy Miller, MD*

- Discussion: Breast Cancer - Local/Regional and Adjuvant Therapy

*Kathy Miller, MD*

- Discussion: Lung Cancer - Metastatic

*Charles M. Rudin, MD, PhD*

- Discussion: Sarcoma

*Gary K. Schwartz, MD*

- Discussion: Gastrointestinal (Noncolorectal) Cancer

*C. D. Blanke, MD*

- Discussion: Head and Neck Cancer

*Everett E. Vokes, MD*

**Session Title:** #40: Developing Drugs in Special Populations: Organ Dysfunction Studies

**Session Type:** Education Session

**Date:** Tuesday, June 8

**Location:** E354b

**Time:** 8:00 AM - 9:15 AM

- Renal dysfunction studies

*Daniel Mulkerin, MD*

- Liver dysfunction studies

*Ghassan K. Abou-Alfa, MD*

- Regulatory considerations for organ dysfunction studies

*Shiew-Mei Huang, PhD*

**Session Title:** #45: Even Patients with Liver Dysfunction Can Get Chemotherapy!

**Session Type:** Education Session

**Date:** Tuesday, June 8

**Location:** E354b

**Time:** 9:45 AM - 11:00 AM

- Understanding assessment of liver function and viral hepatitis for the medical oncologist.

*Lewis R. Roberts, PhD, MBChB*

- Understanding the importance of hepatic function and dysfunction in metabolism of anticancer agents Delivering chemotherapy to the patient with liver dysfunction.

*Timothy W. Synold, PharmD*

- Management of dosing and side effects of specific chemotherapeutic agents.

*Melanie B. Thomas, MD*

**Session Title:** #138: The Best Treatment for Hepatic Metastases: What Is the Evidence?

**Session Type:** Clinical Problems in Oncology Session

**Date:** Tuesday, June 8

**Location:** E451a

**Time:** 9:45 AM - 11:00 AM

- Evidence for patient benefit using surgical and/or ablation for hepatic metastases.

*Bryan M. Clary, MD*

- The incorporation of conventional and stereotactic body radiation therapy into the treatment of hepatic metastases.

*Christopher Willett, MD*

---

**Session Title:** #129: Hepatocellular Carcinoma: Is This Patient a Transplant, Resection, or Chemoembolization Candidate?

**Session Type:** Clinical Problems in Oncology Session

**Date:** Tuesday, June 8

**Location:** E451a

**Time:** 11:30 AM - 12:45 PM

- The role of liver transplantation in management of hepatocellular cancer.

*Lynt Johnson*

- The role of intrahepatic interventions in HCC.

*Riad Salem, MD, MBA*

- The role of hepatic resection in management of HCC patients.

*Timothy Pawlik, MD, MPH*